Trial results

$RZLT — ersodetug

Rezolute, Inc. (RZLT) ersodetug: trial results in Tumor hyperinsulinism (tumor HI), 2026.

Research by Catalyst Intel

The catalyst

"Enrollment is in progress and topline results are expected before the end of 2026."

— Rezolute, Inc., 8-K filed 2026-09-24 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

RZLT-ERSODETUG-2026

Company

Rezolute, Inc.

Kind

Trial results

Indication

Tumor hyperinsulinism (tumor HI)

Window

2026-01-01 – 2026-12-31

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2027-01-30; subscribers get it on the day.